TCT-14 Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 12-month follow-up- BIOSOLVE-II and BIOSOLVE-III

Abstract

Assessment of the safety and clinical performance of the Sirolimus-Eluting Bioabsorbable Magnesium Scaffold (DREAMS 2G) from the combined analysis of BIOSOLVE-II and BIOSOLVE-III studies at 12-month. One hundred eighty four (184) subjects have been enrolled in BIOSOLVE-II and BIOSOLVE-III studies.